Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies

Inclusion criteria * Age ≥ 18 years of age * Life expectancy ≥3 months * Histologically documented advanced solid tumors which have progressed after standard systemic therapy or for which standard systemic therapy does not exist * Agents containing warfarin or heparin must be discontinued 7 days prior to enrollment in the study Exclusion criteria * History of/or active bleeding disorders * Known hypersensitivity to warfarin or related compounds * The use of vitamin K * Central lines that require anticoagulant maintenance * The use of agents containing warfarin and heparin * Known diagnosis of human immunodeficiency virus (HIV) infection, hepatitis Other protocol-defined inclusion/exclusion criteria may apply